RESEARCH ARTICLE
Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis Ning Liu1☯, Zhen Wang1☯, Weidong Gan1*, Lei Xiong1, Baolei Miao1, Xiancheng Chen1, Hongqian Guo1, Dongmei Li2,3* 1 Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China, 2 Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu, China, 3 Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing, Jiangsu, China
a11111
☯ These authors contributed equally to this work. *
[email protected] (WG);
[email protected] (DL)
Abstract OPEN ACCESS Citation: Liu N, Wang Z, Gan W, Xiong L, Miao B, Chen X, et al. (2016) Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis. PLoS ONE 11(11): e0166897. doi:10.1371/journal.pone.0166897 Editor: Donald P Bottaro, National Institute of Health, UNITED STATES Received: August 25, 2016 Accepted: November 4, 2016 Published: November 28, 2016 Copyright: © 2016 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper and its Supporting Information file. Funding: This research was supported by the National Natural Science Foundation of China (ID:81572512). The website of the program is http://www.nsfc.gov.cn/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
To investigate the clinical characteristics, treatments and prognosis of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions (Xp11.2 tRCC), the epidemiological features and treatment results of 34 cases of Xp11.2 tRCC, which were diagnosed by immunohistochemistry staining of TFE3 and fluorescence in situ hybridization at our center, were retrospectively reviewed. The 34 patients included 21 females and 13 males aged 3 to 64 years (median age: 27 years). Four patients were children or adolescents (
